Theragnostic imaging using radiolabeled antibodies and tyrosine kinase inhibitors

Area of Science:

• Oncology
• Molecular Imaging
• Pharmacology

Background:

• Molecular targeted therapies, including tyrosine kinase inhibitors (TKIs) and monoclonal antibodies, are now standard cancer treatments.
• Despite their efficacy, these therapies can cause unexpected adverse effects or suboptimal therapeutic outcomes.
• Accurate diagnostic tools are needed to assess target molecule status, predict treatment response, and anticipate adverse events.

Purpose of the Study:

• To review the development and clinical applications of novel radiolabeled molecular imaging probes.
• To discuss the utility of these probes in evaluating molecular targeted therapy.
• To highlight challenges and future directions for molecular imaging in precision oncology.

Main Methods:

• Review of current literature on radiolabeled TKIs and antibodies for molecular imaging.
• Discussion of conventional diagnostic methods like immunohistochemistry, PCR, and FISH.
• Exploration of positron emission tomography (PET) and single photon emission computed tomography (SPECT) for noninvasive molecular assessment.

Main Results:

• Radiolabeled TKIs and antibodies show promise for noninvasive molecular imaging in targeted cancer therapy.
• Molecular imaging can provide insights into gene/protein expression and drug pharmacokinetics.
• These techniques offer potential for personalized treatment strategies and improved patient outcomes.

Conclusions:

• Molecular imaging probes are valuable tools for guiding molecular targeted therapy.
• Noninvasive assessment of drug targets and pharmacokinetics can optimize cancer treatment.
• Further research is needed to address current limitations and enhance the clinical utility of these imaging agents.